Evidence map›Paper›PMID 42388018›Full record

ArticleBritish journal of clinical pharmacology2026

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.

Nele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, Juan José Perez Ruixo, Saberi Rana Ali, Iolanda Cirillo, Oliver Ackaert

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nele GoeyvaertsJohnson & Johnson, Beerse, Belgium.ORCID https://orcid.org/0000-0003-0526-5318
Per Olsson GisleskogPOG Pharmacometrics, London, UK.ORCID https://orcid.org/0000-0002-0706-8783
Martine NeyensJohnson & Johnson, Beerse, Belgium.ORCID https://orcid.org/0009-0006-0959-3924
Juan José Perez RuixoJohnson & Johnson, Madrid, Spain.ORCID https://orcid.org/0000-0001-9890-745X
Saberi Rana AliJohnson & Johnson, Titusville, New Jersey, USA.ORCID https://orcid.org/0009-0009-1581-8431
Iolanda CirilloJohnson & Johnson, Raritan, New Jersey, USA.
Oliver AckaertJohnson & Johnson, Beerse, Belgium.ORCID https://orcid.org/0000-0002-5908-5200

Funding

Johnson & Johnson
6 · The paper itself

Abstract

aimsCanagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed-dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated exposure metrics for QD and BID doses in paediatric patients and adults, and investigate the relationship between canagliflozin plasma concentrations and change from baseline HbA1c with QD and BID doses.

methodsPaediatric population pharmacokinetics and pharmacokinetics/pharmacodynamics models were based on the previously developed corresponding adult models, using Phase 1 and 3 study data, evaluating canagliflozin 100- or 300-mg QD doses in paediatric patients with T2DM. Modelling encompassed exploratory analysis, external evaluation, model update and simulation of canagliflozin exposure metrics and HbA1c for QD and BID doses.

resultsEstimated and simulated steady-state area under the concentration-time curve during 24 h (AUC

conclusionsNo canagliflozin dose adjustments are required alone or in combination with metformin to ensure similar plasma exposures between paediatric and adult patients with T2DM, as well as similar HbA1c lowering between QD and BID dosing in paediatric patients.

Indexed as

CanagliflozinDiabetes Mellitus, Type 2Hypoglycemic AgentsModels, BiologicalSodium-Glucose Transporter 2 InhibitorsAdolescentAdultAge FactorsArea Under CurveChildComputer SimulationDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleGlycated HemoglobinCanagliflozinGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 Inhibitorscanagliflozindiabetes mellitusmodellingpaediatricspharmacodynamicspharmacokineticssimulation

Identifiers

PMID42388018
PMCPMC13619081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.